Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma

Background: Quantitative drug benefit–risk assessment (BRA) helps assess the magnitude of benefit and risk of new cancer therapies. This BRA aimed to summarize the evidence for the benefits and risks of ivosidenib versus placebo for the treatment of previously treated, locally advanced or metastatic...

Descrizione completa

Dettagli Bibliografici

Autori principali:	J.W. Valle, G.K. Abou-Alfa, R.K. Kelley, M.A. Lowery, R.T. Shroff, Y. Bian, G. Saint-Hilary, H. Liu, Z. Teng, Z. Hua, C. Gliser, A. Vogel, M.M. Javle
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-06-01
Serie:	ESMO Gastrointestinal Oncology
Soggetti:	quantitative drug benefit–risk assessment cholangiocarcinoma mutant isocitrate dehydrogenase-1 ivosidenib
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2949819825000287
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!